Tata Sons to sell 23 crore shares of Tata Capital in IPO, shows updated DRHP
(You can now subscribe to our
(You can now subscribe to our ETMarkets WhatsApp channel
As the RBI's September deadline nears, Tata Capital has filed its updated Draft Red Herring Prospectus (DRHP) with the markets regulator Sebi. The filing shows that promoter group Tata Sons plans to sell 23 crore shares of the NBFC, while the International Finance Corporation will offload another 3.58 crore shares in the much-awaited IPO.In addition to the offer for sale (OFS) by the two shareholders, the Tata Capital IPO also includes a fresh issue of up to 21 crore shares. While some reports peg the IPO size at around Rs 17,200 crore, if the company prices the issue at the same Rs 281 per share as the rights issue conducted in March, the size could be closer to Rs 13,371 crore.The IPO price band and launch dates are yet to be announced.According to the updated DRHP, the total offer size stands at 47.58 crore equity shares. For FY24, Tata Capital reported a consolidated net worth of Rs 16,250 crore and a profit after tax of Rs 2,142 crore.The DRHP shows that 95.5% stake in the company is owned by promoters, with Tata Sons owning 88.6% stake. Other owners include TMF Holdings, Tata Investment Corporation , IFC, Tata Motors , and Tata Chemicals Also Read | Sebi approves Tata Capital's confidential DRHP for Rs 17,200 crore IPO Under the provisions of the NBFC Scale-Based Regulations, shares of Tata Capital are required to be mandatorily listed on stock exchanges within three years of identification as the NBFC upper layer i.e., on or prior to September 30, 2025.Upper-layer NBFCs are those selected by the RBI based on certain rules and criteria that require them to follow stricter regulations. In January, the RBI named 15 such NBFCs for 2024-25, including Tata Capital.Earlier last month, ET had reported that Sebi has approved the confidential DRHP filed by Tata Capital on April 5.Tata Capital's unlisted shares, which have fallen by around 16% in the last month, were trading at about Rs 865 on the Unlisted Zone platform.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
14 minutes ago
- India.com
India's Pharma Exports Have Shot Up By 92% In Last 6 Years: Minister
New Delhi: Various schemes being implemented by the Centre to realise the vision of Aatmanirbhar Bharat in the pharmaceutical sector have resulted in India's exports of drugs and pharmaceuticals increasing by 92 per cent, from Rs 1,28,028 crore in FY2018-19 to Rs 2,45,962 crore in FY2024-25, the Parliament was informed on Friday. The schemes include the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, the PLI Scheme for Bulk Drugs, Scheme for Promotion of Bulk Drug Parks, and Strengthening of Pharmaceutical Industry scheme, Minister of State for Chemicals and Fertilisers Anupriya Patel told the Lok Sabha in a written reply to a question. The PRIP scheme has been launched with an outlay of Rs 5,000 crore to transform India's Pharma MedTech sector from cost- to innovation-based growth by strengthening research and promoting industry-academia linkage for research and development in priority areas in drug discovery and development and medical devices. Under this scheme, seven Centres of Excellence (CoEs) have been set up, she said. The PLI Scheme for Pharmaceuticals aims to enhance India's manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. The minister said that the scheme has enabled enhanced investment and production in eligible products. As of March 2025, the committed investment of Rs 17,275 crore targeted over the six-year period of the scheme stands substantially exceeded with a cumulative investment of Rs 37,306 crore made by the scheme's third year, and cumulative sales of approved products of Rs 2,66,528 crore have been made, including exports of Rs 1,70,807 crore. The PLI Scheme for Bulk Drugs, which has a total budgetary outlay of Rs 6,940 crore, aims to avoid disruption in the supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on a single source. As of March 2025, the committed investment of Rs 3,938.5 crore under projects approved under the scheme for investment over the six-year production period of the scheme stands substantially exceeded with a cumulative investment of Rs 4,570 crore made by the scheme's third year, she further stated. The minister also highlighted that the government launched the Pradhan Mantri Bhartiya Janaushadhi Pariyojana scheme to make quality generic medicines available at affordable prices to all. Under the scheme, dedicated outlets known as Jan Aushadhi Kendras (JAKs) are opened across the country to provide medicines at prices that are about 50 per cent to 80 per cent lower than those of leading branded medicines in the market. Till June 6, 2025, a total of 16,912 JAKs have been opened, and on average, about 10 to 12 lakh persons visit these Kendras daily and avail of quality medicines at affordable prices. As many as 2,110 medicines and 315 surgicals, medical consumables and devices are under the scheme product basket, covering all major therapeutic groups, such as cardiovascular, anti-cancer, anti-diabetic, anti-infectives, anti-allergic and gastro-intestinal medicines and nutraceuticals. As a result of the scheme, in the last 11 years, estimated savings of about Rs 38,000 crore have accrued to citizens in comparison to the prices of branded medicines. Further, the scheme has provided self-employment to over 16,000 persons, including over 6,800 women entrepreneurs, the minister added.
Economic Times
14 minutes ago
- Economic Times
RBI's oversubscribed VRRR auction signals strong bank participation amid falling overnight rates
Mumbai: The seven-day variable rate reverse repo (VRRR) auction Friday was oversubscribed as banks preferred parking funds with Mint Road amid a fall in overnight money market rates after the central bank stepped in to keep them anchored around the policy repo rate of 5.5%. ADVERTISEMENT Lower auction size and expectations of further improvement in the liquidity conditions next week led to higher participation, bank treasury dealers said. Against the notified amount of ₹1.25 lakh crore, the Reserve Bank of India (RBI) received bids worth ₹1.42 lakh crore. The cut-off and weighted average rates came in at 5.49% and 5.48%, respectively, higher than the overnight rates. "Generally, the participation in VRRR is higher when the overnight rates are down, which was the case on Friday," said Ritesh Bhusari, joint GM, South Indian Bank. "While banks park money depending on the liquidity requirements for a week, there is also growing comfort that the RBI will come with repo auctions to infuse liquidity, if needed, to keep rates in the LAF (liquidity adjustment facility) corridor." On Friday, weighted average call rate (WACR), which acts as the operative rate for monetary policy transmission, fell to 5.39% compared with 5.54% on Thursday. (You can now subscribe to our ETMarkets WhatsApp channel)
News18
21 minutes ago
- News18
Hyundai India Gets Rs 517.34 Cr Tax With Penalty Demand From GST Authority, Here's Why
Last Updated: The company said there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. Hyundai Motor India Ltd on Tuesday said it has received a demand of Rs 517.34 crore from tax authorities, along with penalty, for alleged short payment of GST compensation cess on its certain SUV models. The company has received an order from Commissioner (Appeals), CGST Dept, Tamil Nadu, confirming GST compensation cess demand of Rs 258.67 crore, along with penalty of Rs 258.67 crore, on the allegation of short payment of GST compensation cess on certain SUV models for the period September 2017 – March 2020, Hyundai Motor India Ltd said in a regulatory filing. Reacting to the demand, a company spokesperson said, 'HMIL is of the view that the amendment and the clarifications given by the Central Board of Indirect Tax and Customs (CBIC) to resolve the issue faced by the industry on this matter are in favour of the company. We are in the process of reviewing the order and will exercise the right to seek a legal remedy through an appropriate forum." The company asserted that there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. . view comments First Published: July 26, 2025, 08:17 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
